Gut Health Research

IBS-C Constipation Treatment Management: Integrating Natural Products and Meal Timing Constipation-predominant irritable bowel syndrome (IBS-C) challeng…

Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: Overlap, Recurrence, and Evidence-Based Treatment A 2026 systematic review of 55 cli…

Introduction Short-chain fatty acids (SCFAs) like butyrate are not just byproducts of digestion

Evidence-Based IBS-C Constipation Treatment Management Irritable bowel syndrome with constipation (IBS-C) remains a complex challenge, where simple laxa…

A 2026 Systematic Review Clarifies Best Treatments for SIBO-IBS Symptom Overlap In a 2026 systematic review published in World J Methodol , researchers …

Pathophysiology-Driven Natural Products for IBS-C A 2026 review in Naunyn-Schmiedeberg’s Archives of Pharmacology consolidates evidence that certain nat…

A systematic review published in 2026 analyzed 55 clinical trials and found the antibiotic rifaximin to be the most consistently effective treatment for…

Evidence-Based IBS-C Constipation Treatment: A 2026 Research Update Irritable Bowel Syndrome with constipation (IBS-C) is characterized by chronic abdom…

Rifaximin Efficacy of 83.3% Drives Treatment for IBS and SIBO Overlap A 2026 systematic review of 55 studies analyzed the comparative effectiveness of M…

The Molecular Blueprint of a Butyrate Producer Short-chain fatty acids (SCFAs) like butyrate are the cornerstone of gut health, fueling colon cells and …

A New Framework for IBS-C: Moving Beyond Symptom Control Irritable bowel syndrome with constipation affects millions, yet many find standard treatments …

Rifaximin Demonstrated Most Consistent Efficacy for IBS-D and SIBO in Systematic Review of 55 Studies A 2026 systematic review in World J Methodol analy…